Skip to content
WorldBrand.AI

Andon

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2022

    Selective disclosure of COVID test kit results leads to regulatory talks for chairman and board secretary

    In January 2022, during a sharp rise in Andon Health's share price, the company disclosed only partial positive results from its COVID antigen test kit in Omicron experiments, but did not disclose that samples with higher CT values had only a 60% detection rate, nor the missed-detection results. The Shenzhen Stock Exchange sent a letter of concern questioning selective disclosure and stock speculation; the Tianjin Securities Regulatory Bureau found the information disclosure incomplete and took regulatory talk measures against chairman Liu Yi and board secretary Wu Tong. Regulatory talk.

    Source